Target Entity: A1 Biochem Labs LLC

Type of Deal: Acquisition of 100% membership interest

Stake/Capacity: 100% ownership acquired

Deal Value: USD 15.247 million (cash consideration)

Funding Source: Not disclosed

Financial Impact:

  • Target company financials: USD 6.35 million revenue (2023), USD 9.23 million revenue (2024), USD 5.92 million revenue (2025)
  • Expected to expand portfolio and facilitate full service, longer life cycle engagement with customers
  • No specific accretion/dilution or synergy expectations disclosed

Timeline: Acquisition completed on October 2, 2026

Strategic Rationale:

  • Expands presence in the life cycle of Active Pharmaceutical Ingredients (API) business
  • Creates a dedicated Contract Research, Development and Manufacturing (CRDMO) platform
  • Adds front-end research and development capability to complement existing large-scale API manufacturing
  • Facilitates full service, longer life cycle engagement with customers
  • Complementary to current API manufacturing business of Apitoria and A1 Labs India

Approval Status: Completed on October 2, 2026, subject to customary conditions under Definitive Agreements

Reference Regulation: SEBI Regulation 30

Additional Details:

  • A1 Labs LLC operates from a scientific laboratory in Wilmington, North Carolina, USA
  • Incorporated in September 2015
  • Engaged in contract research and chemistry services including custom synthesis and medicinal chemistry
  • Led by Dr. Rajendra Gadikota who has 25+ years of experience and will continue employment post-acquisition
  • Transaction classified as related party transaction (Dr. Gadikota is Director of A1 Labs India)
  • Conducted at arm's length
  • No governmental or regulatory approvals required
  • A1 USA Inc (wholly owned subsidiary of A1 Labs India) acquired 100% membership interest